Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan D Richman

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|July 13, 2021
Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backboneSanne Ten Hoorn, Dirkje W Sommeijer, Faye Elliott, et al.
Scientific Reports|February 5, 2021
Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNAThomas L Dunwell, Simon C Dailey, Anine L Ottestad, et al.
The Journal of Pathology|December 23, 2015
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trialsSusan D Richman, Katie Southward, Philip Chambers, et al.
Scientific Reports|September 19, 2024
The ATOM-Seq sequence capture panel can accurately predict microsatellite instability status in formalin-fixed tumour samples, alongside routine gene mutation testingKanishta Srihar, Arief Gusnanto, Susan D Richman, et al.
BMJ Open|November 10, 2025
Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trialRussell Frood, Alexandra Gilbert, Duncan Gilbert, et al.
NPJ Precision Oncology|April 9, 2024
Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapyMaxime W Lafarge, Enric Domingo, Korsuk Sirinukunwattana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2014
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studiesSabine Venderbosch, Iris D Nagtegaal, Tim S Maughan, et al.
Cell Reports. Medicine|March 23, 2023
Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric studyJan Moritz Niehues, Philip Quirke, Nicholas P West, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2021
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N TrialRichard A Adams, David J Fisher, Janet Graham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2021
Inhibition of WEE1 Is Effective in <i>TP53</i>- and <i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active MonitoringJenny F Seligmann, David J Fisher, Louise C Brown, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|July 13, 2021
Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backboneSanne Ten Hoorn, Dirkje W Sommeijer, Faye Elliott, et al.
Scientific Reports|February 5, 2021
Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNAThomas L Dunwell, Simon C Dailey, Anine L Ottestad, et al.
The Journal of Pathology|December 23, 2015
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trialsSusan D Richman, Katie Southward, Philip Chambers, et al.
Scientific Reports|September 19, 2024
The ATOM-Seq sequence capture panel can accurately predict microsatellite instability status in formalin-fixed tumour samples, alongside routine gene mutation testingKanishta Srihar, Arief Gusnanto, Susan D Richman, et al.
BMJ Open|November 10, 2025
Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trialRussell Frood, Alexandra Gilbert, Duncan Gilbert, et al.
NPJ Precision Oncology|April 9, 2024
Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapyMaxime W Lafarge, Enric Domingo, Korsuk Sirinukunwattana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2014
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studiesSabine Venderbosch, Iris D Nagtegaal, Tim S Maughan, et al.
Cell Reports. Medicine|March 23, 2023
Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric studyJan Moritz Niehues, Philip Quirke, Nicholas P West, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2021
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N TrialRichard A Adams, David J Fisher, Janet Graham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2021
Inhibition of WEE1 Is Effective in <i>TP53</i>- and <i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active MonitoringJenny F Seligmann, David J Fisher, Louise C Brown, et al.
Pageof 5